Table 1.
Patient characteristics and clinical features.
| No. | Sex/age at cancer onset | Cancer | Oncologic treatment | Treatment response | Interval of BP onset after last ICI initiation | Age at BP onset | BP phenotype | BPDAI | BP treatment | BP duration | Other irAE |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/67 | MM | P 2nd line (17 cycles) |
CR | 12 months | 73 | Pruritic, non-bullous, palmoplantar | >57 (sev) | tGCS, sGCS dapsone rituximab |
12 months | Nephritis Hypophysitis |
| 2 | M/50 | DM | P 1st line (24 cycles) |
CR | 15 months | 72 | Urticarial, bullous, palmar | 49 (mod) | tGCS, sGCS dapsone rituximab |
9 months | Vitiligo Thyreoiditis |
| 3 | M/51 | NM | N 2nd line (32 cycles) |
CR | 21 months | 62 | Bullous postinflammatory milia, plantar | 47 (mod) | tGCS, sGCS | 2 months | Nephritis Hepatitis Alopecia Areata totalis |
| 4 | M/77 | NM | P 1st line (24 cycles) |
PD | 15 months | 80 | Urticarial, bullous, palmoplantar | >57 (sev) | tGCS, sGCS docycycline dapsone |
19 months | None |
| 5 | M/69 | MUP | N 1st line (5 cycles) |
PR | 9 months | 70 | Localized, bullous | NA (mild) | tGCS, sGCS dapsone |
6 months | None |
| 6 | F/64 | MCC | N 1st line (2cycles) | CR | 2 months | 65 | Localized, plantar | 6 (mild) | tGCS | 2 months | Oral lichen planus |
| 7 | M/26 | SCC | C 2nd line | PD | 3 months | 26 | Bullous | >57 (sev) | tGCS | 6 months | None |
| 8 | M/60 | HCC | N-L 1st line (5 cycles) |
CR | 6 months | 60 | Urticarial, bullous, palmoplantar, oral mucosa | >57 (sev) | tGCS, sGCS doxycycline |
Ongoing | None |
MUP, melanoma of unknown primary; C, cemiplimab; DM, desmoplastic melanoma; F, female; HCC, hepatocellular carcinoma; M, male; MCC, Merkel cell carcinoma; MM, malignant melanoma; N, nivolumab; NM, nodular malignant melanoma; N-L, nivolumab–lenvatinib; P, pembrolizumab; SCC, squamous cell carcinoma; tGCS, topical glucocorticosteroids; sGCS, systemic glucocorticosteroids.